A number of other research firms also recently commented on AZN. Barclays reiterated an overweight rating and issued a GBX 6,600 ($85.97) price objective (up previously from GBX 6,500 ($84.67)) on shares of AstraZeneca in a report on Friday, August 10th. HSBC set a GBX 4,840 ($63.05) price objective on shares of AstraZeneca and gave the company a sell rating in a report on Wednesday, August 15th. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 6,500 ($84.67) price objective on shares of AstraZeneca in a report on Tuesday, August 21st. Liberum Capital reiterated a hold rating on shares of AstraZeneca in a report on Thursday, August 23rd. Finally, Jefferies Financial Group set a GBX 6,200 ($80.76) price objective on shares of AstraZeneca and gave the company a neutral rating in a report on Thursday, August 16th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the company. The stock has a consensus rating of Hold and an average target price of GBX 5,689.45 ($74.11).
AZN stock opened at GBX 5,959 ($77.62) on Monday. AstraZeneca has a 12 month low of GBX 4,260 ($55.49) and a 12 month high of GBX 5,520 ($71.90).
The company also recently declared a dividend, which was paid on Monday, September 10th. Stockholders of record on Thursday, August 9th were issued a dividend of GBX 68.40 ($0.89) per share. The ex-dividend date of this dividend was Thursday, August 9th. This represents a dividend yield of 1.19%.
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.